Morgan Stanley
SPRB

Morgan Stanley’s Spruce Biosciences SPRB Stock Holding History

Morgan Stanley’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
4,411
+2,996
+212% +$167K ﹤0.01% 5879
2026
Q1 		$92.5K Buy
1,415
+1,027
+265% +$70.8K ﹤0.01% 6196
2025
Q4 		$33.8K Buy
388
+290
+296% +$31.1K ﹤0.01% 6547
2025
Q3 		$878 Buy
+98
New +$868 ﹤0.01% 7401
2025
Q2 		– Sell
-99
Closed -$2.15K – 8347
2025
Q1 		$2.15K Buy
99
+71
+254% +$1.98K ﹤0.01% 7163
2024
Q4 		$896 Hold
28
– – ﹤0.01% 7289
2024
Q3 		$1.01K Hold
28
– – ﹤0.01% 7217
2024
Q2 		$1.1K Sell
28
-259
-90% -$13.9K ﹤0.01% 7141
2024
Q1 		$16.9K Buy
287
+230
+404% +$58.5K ﹤0.01% 6539
2023
Q4 		$12.5K Buy
57
+29
+104% +$3.35K ﹤0.01% 6784
2023
Q3 		$4.82K Hold
28
– – ﹤0.01% 6923
2023
Q2 		$4.58K Sell
28
-14
-33% -$2.34K ﹤0.01% 7006
2023
Q1 		$6.96K Sell
42
-3
-7% -$557 ﹤0.01% 6985
2022
Q4 		$3.66K Sell
45
-264
-85% -$22.1K ﹤0.01% 7233
2022
Q3 		$31K Sell
309
-500
-62% -$69.9K ﹤0.01% 6614
2022
Q2 		$106K Buy
809
+657
+432% +$84.2K ﹤0.01% 6244
2022
Q1 		$22K Sell
152
-13
-8% -$2.42K ﹤0.01% 7112
2021
Q4 		$55K Sell
165
-847
-84% -$252K ﹤0.01% 6770
2021
Q3 		$456K Sell
1,012
-623
-38% -$391K ﹤0.01% 5556
2021
Q2 		$1.38M Buy
1,635
+1,178
+258% +$1.26M ﹤0.01% 4897
2021
Q1 		$569K Buy
457
+386
+544% +$593K ﹤0.01% 5080
2020
Q4 		$129K Buy
+71
New +$118K ﹤0.01% 5806

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Morgan Stanley's SPRB Position: Q2 2026 in Review

Morgan Stanley increased its Spruce Biosciences (SPRB) stake by 212% in Q2 2026, buying an estimated $167K and bringing the position to 4,411 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #5879.

Morgan Stanley first reported a position in SPRB in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.38M in Q2 2021. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Morgan Stanley held 4,411 shares of Spruce Biosciences worth $238K as of Q2 2026.
  • Morgan Stanley bought 2,996 Spruce Biosciences shares in Q2 2026, an estimated $167K.
  • Spruce Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5879 holding.
  • Morgan Stanley first reported a position in Spruce Biosciences in Q4 2020 and has held it in 22 quarters since.
  • Morgan Stanley's Spruce Biosciences position peaked at $1.38M in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.